Frondoside A has an anti-invasive effect by inhibiting TPA-induced MMP-9             activation via NF-κB and AP-1 signaling in human breast cancer cells.
Metastasis and invasion are among the main causes of death in patients with             malignant tumors. The aim of this study was to determine the anti-invasive activity             of frondoside A against human breast cancer cells. We investigated the inhibitory             effect of frondoside A on cell clonogenicity, invasion and migration in TPA-stimulated             human breast cancer cells at non-cytotoxic concentrations. Frondoside A significantly             attenuated TPA-induced colony formation, invasion and migration in MBA-MB-231             human breast cancer cells. Induction of MMP-9 is especially important for the             metastasis of many cancer tumor cell types. Additionally, we found that frondoside A             suppresses TPA-induced MMP-9 enzymatic activity, secretion and expression. This             effect was associated with reduced activation of AP-1 and NF-κB, and correlated             with enhanced expression of TIMP-1 and TIMP-2. Frondoside A significantly inhibited             the TPA-induced MMP-9 expression possibly via the suppression of AP-1 and NF-κB             signaling pathways. Frondoside A reduces the activation of the PI3K/Akt, ERK1/2             and p38 MAPK signals. These results suggest that the anti-metastatic effects of             frondoside A on human breast cancer cells might result from inhibited TPA activation             of AP-1 and NF-κB and reduced TPA activation of PI3K/Akt, ERK1/2 and p38 MAPK             signals, ultimately leading to downregulation of MMP-9 expression. These results             indicate the role of frondoside A in metastasis and its underlying molecular mechanisms,             thus, suggesting frondoside A as a chemopreventive agent for metastatic breast             cancer.
Bio-IT Fusion Technology Research Institute, Busan 609-735, Republic                     of Korea.
Sun Young
SY
Park
Young Hun
YH
Kim
Younghee
Y
Kim
Sang-Joon
SJ
Lee
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005260:Female; D006027:Glycosides / Q000494:pharmacology*; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D016328:NF-kappa B / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000517:prevention & control; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D034622:RNA Interference; D034741:RNA, Small Interfering; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D018808:Transcription Factor AP-1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014315:Triterpenes / Q000494:pharmacology*; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
D000970:Antineoplastic Agents; D006027:Glycosides; D016328:NF-kappa B; D034741:RNA, Small Interfering; D018808:Transcription Factor AP-1; D014315:Triterpenes; C534797:frondoside A; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D048049:Extracellular Signal-Regulated MAP Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D020780:Matrix Metalloproteinase 9; D013755:Tetradecanoylphorbol Acetate